Estradiol-mediated Inflammation and Central Sensitization in the Pathophysiology of Endometriosis-associated Pelvic Pain

NCT07100782

Status	RECRUITING
Phase	Phase 3
Sponsor	University of Michigan
Enrollment	130 participants

Key Eligibility Criteria

Inclusion (20)

- Premenopausal woman between age 18 and 49 years (inclusive) at the time of consent. Menopause is defined as amenorrhea \>1 year unrelated to hormonal suppression.
- History of endometriosis diagnosed by surgery (visual or biopsy confirmed), ultrasound, or MRI within 10 years of study entry
- History of self-reported moderate to severe pelvic pain for e 6 months' duration at time of screening visit.
- Willingness to participate in a relugolix CT drug intervention trial
- Has not used an injectable hormone therapy in the past 6 months (e.g. DepoProvera®, DepoLupron®).

... and 15 more (see full listing online)

Exclusion (21)

- Contraindication to the use of relugolix CT (high risk of arterial or venous thrombotic, or thromboembolic disorder, known osteoporosis, current or history of breast cancer or other hormone sensitive malignancy, known hepatic impairment or disease, undiagnosed abnormal uterine bleeding, known hypersensitivity to components of relugolix CT).
- Concurrent participation in other therapeutic trials
- Pregnant, lactating, less than 6 months postpartum, or planning a pregnancy within next 12 months
- Planning pelvic or abdominal surgery during study period
- Prior major surgery in the past 4 months that involves incisions on the abdomen, chest, head, other than a skin biopsy (hysteroscopy, endometrial biopsy is ok to include).

... and 16 more (see full listing online)

Locations (1 total)

University of Michigan, Ann Arbor, Michigan, United States